Oral Delivery of Proteins and Peptides: Concepts and Applications - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 519

[112] Davis SS. Advanced delivery systems for peptides and proteins-pharmaceutical. In:
Davis SS, Tomlinson E, editors. Delivery systems for peptide drugs. New York/London:
NATO Advanced Science Institutes Series; 1986. p. 1-21.
[113] Chikhale EG, Ng KY, Burton PS, Borchardt RT. Hydrogen bonding potential as a deter-
minant of the in vitro and in situ blood-brain barrier permeability of peptides. Pharm
Res 1994;11:412-19.
[114] Siegel IA. Permeability of the oral mucosa. In: Meyer J, Squier CA, Gerson SJ, editors.
The structure and function of oral mucosa. Oxford, England: Oxford University Press;
1984. p. 95-108.
[115] Chikhale EG, Burton PS, Borchardt RT. The effect of verapamil on the transport of pep-
tides across the blood-brain barrier in rats: kinetic evidence for an apically polarized
efflux mechanism. J Pharmacol Exp Ther 1994;273:298-303.
[116] Diamond JM, Wright EM. Molecular forces governing non-electrolyte permeation
through cell membranes. Proc R Soc B 1969;172:273-316.
[117] Lee HLV. Oral route of peptide and protein drug delivery. BioPharm 1992;5:39-50.
[118] Pantzar N, Lundin S, Westrom BR. Different properties of the paracellular pathway
account for the regional small intestinal permeability to the peptide desmopressin.
J Pharm Sci 1995;84:1245-8.
[119] Lundin S, Pantzar N, Broeders A, Ohlin M, Westrom BR. Differences in transport rate
of oxytocin and vasopressin analogues across proximal and distal isolated segments of
the small intestine of the rat. Pharm Res 1991;8:1274-80.
[120] Schilling RJ, Mitra AK. Pharmacodynamics of insulin following intravenous and enteral
administrations of porcine-zinc insulin to rats. Pharm Res 1992;9:1003-9.
[121] Lu RH, Kopeckova P, Kopecek J. Degradation and aggregation of human calcitonin in
vitro . Pharm Res 1999;16:359-67.
[122] Touitou E, Rubinstein A. Targeted enteral delivery of insulin to rats. Int J Pharm
1986;30:95-9.
[123] Quadros E, Landzert NM, LeRoy S, Gasparani F, Worosila G. Colonic absorption of
insulin-like growth factor I in vitro . Pharm Res 1994;11:226-30.
[124] Ashford M, Fell JT. Targeting drugs to the colon: delivery systems for oral administra-
tion. J Drug Target 1994;2:241-57.
[125] Shakweh M, Ponchel G, Fattal E. Particle uptake by Peyer's patches: a pathway for
drug and vaccine delivery. Expert Opin Drug Deliv 2004;1:141-63.
[126] Zhou XH. Overcoming enzymatic and absorption barriers to non-parenterally adminis-
tered protein and peptide drugs. J Control Release 1994;29:239-52.
[127] Hughes RA, Toth I, Ward P, Ireland SJ, Gibbons WA. Lipidic peptides. III: lipidic amino
acid and oligomer conjugates of morphine. J Pharm Sci 1991;80:1103-5.
[128] Taniguchi T, Tomoda Y, Tanaka Y, Murakami M, Yamamoto A, Muranishi S. Synthesis of
acyloyl lysozyme and improvement of its lymphatic transport following small intestinal
administration in rats. Proc Int Symp Control Release Bioact Mater 1992;19:104-5.
[129] Asada H, Douen T, Waki M, Adachi S, Fujita T, Yamamoto A, et al. Absorption charac-
teristics of chemically modified-insulin derivatives with various fatty acids in the small
and large intestine. J Pharm Sci 1995;84:682-7.
[130] Asada H, Douen T, Murakami M, Yamamoto A, Muranishi S. Improvement of intestinal
absorption of insulin by chemical modification with fatty acids. Proc Int Symp Control
Release Bioact Mater 1992;19:212-3.
[131] Yamada K, Murakami M, Yamamoto A, Takada K, Muranishi S. Improvement of intes-
tinal absorption of thyrotropin-releasing hormone by chemical modification with lauric
acid. J Pharm Pharmacol 1991;44:717-21.